πŸ‡ΊπŸ‡Έ FDA
Patent

US 7494660

HCV NS3-NS4A protease resistance mutants

granted A61KA61K38/162A61P

Quick answer

US patent 7494660 (HCV NS3-NS4A protease resistance mutants) held by Vertex Pharmaceuticals Incorporated expires Mon Feb 19 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Feb 24 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 19 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K38/162, A61P, A61P1/16, A61P31/12